Trial
NCT06617455
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
Breast Cancer Research Foundation
Condition
Anatomic Stage I Breast Cancer AJCC v8
Intervention
Biospecimen Collection
Why stopped
Lack of Patient Interest
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-06